Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX)
Rhea-AI Filing Summary
Kyverna Therapeutics, Inc. filed an initial Form 3 for director Andrew Craig Miller. This filing identifies him as a board member of Kyverna Therapeutics (ticker KYTX) and establishes his status as an insider subject to ongoing ownership reporting requirements.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Kyverna Therapeutics (KYTX) Form 3 filed for Andrew Craig Miller show?
The Form 3 for Andrew Craig Miller shows he is a director of Kyverna Therapeutics, Inc. (KYTX). It is an initial statement of beneficial ownership, formally designating him as an insider subject to future ownership reporting.
Who is the reporting person on the Kyverna Therapeutics (KYTX) Form 3?
The reporting person is Andrew Craig Miller, listed as a director of Kyverna Therapeutics, Inc. This means he serves on the company’s board and must comply with insider reporting obligations under U.S. securities regulations.
Does the Kyverna Therapeutics (KYTX) Form 3 report any buy or sell transactions?
The Form 3 summary for Kyverna Therapeutics, Inc. shows no reported buy, sell, acquire, or dispose transactions. All transaction counts and share amounts are zero, indicating only an initial insider status filing for the director.
What is the significance of a Form 3 filing for Kyverna Therapeutics (KYTX)?
A Form 3 filing establishes an individual as a beneficial owner or insider of Kyverna Therapeutics, Inc. It marks the starting point for future ownership change reports on Forms 4 or 5, improving transparency around insider holdings.
Is Andrew Craig Miller a 10% owner of Kyverna Therapeutics (KYTX) according to the Form 3?
According to the Form 3 details, Andrew Craig Miller is listed as a director and not a ten percent owner of Kyverna Therapeutics, Inc. The “ten percent owner” flag is set to zero for this reporting person.